Tinidazole in upper respiratory air-way infection

Evidence of tinidazole interference in the oropharyngeal inflammatory process during infectious mononucleosis

The efficacy of tinidazole was studied in 24 patients with infectious mononucleosis (IM), 13 of whom were randomized for 5 days of tinidazole treatment and 11 for control without placebo. In judging the comparability of the 2 groups not only was the distribution of confounding factors such as age, sex or duration of symptoms before admission considered, but also the distribution of the Epstein-Barr virus (EBV) serological stage at entry. In these respects the groups were well matched. The duration of sore throat and pharyngotonsillitis after admission was significantly shorter for the patients treated with tinidazole than for the controls. Orosomucoid and lactodehydrogenase concentrations normalized more readily in IM patients with a short duration of sore throat after admission and in patients treated with tinidazole compared to those with a long duration of sore throat and to the tinidazole controls. Clinical and laboratory findings were thus parallel and showed a clinical effect of tinidazole, believed to be mediated via the well-known activity of this drug against anaerobic bacteria. The EBV serological stage of each patient at entry could not predict the duration of symptoms. The results showed that the course of the angina was not primarily dependent on the virus host interaction but probably on other factors, still unknown. One such factor could be the balance between the mucosal defence and the normal oropharyngeal microflora.

The effect of tinidazole on primary EBV infection and immunocompetence

Tinidazole and metronidazole have been reported beneficial in the treatment of acute anginose infectious mononucleosis. As this disease is caused by the Epstein-Barr virus (EBV), the effect of tinidazole on EBV infection of human B-lymphocytes was investigated. Tinidazole had no effect on induction of EBV determined nuclear antigen (EBNA) or DNA synthesis, while immunoglobulin synthesis was increased in the presence of the drug. Cytotoxicity directed against EBV positive cell lines and long term T-lymphocyte mediated anti-EBV memory, were not affected by tinidazole. In view of these findings we suggest that tinidazole does not act directly on the primary EBV infection in vitro. Nor do our findings indicate any adverse effects of tinidazole on the virus-host relation.

Tinidazole--microbiology, pharmacology and efficacy in anaerobic infections

Tinidazole is a 5-nitroimidazole with selective activity against anaerobic bacteria and protozoa. It is bactericidal at low concentrations and its spectrum covers most anaerobic bacteria and some capnophilic microorganisms. Anaerobic bacteria known to be resistant to tinidazole include anaerobic streptococci, actinomyces and propionibacteria. Tinidazole is one of the most active antibacterial agents against Bacteroides fragilis which is one of the most resistant species of anaerobic bacteria. Only a few strains have been reported to be resistant. Tinidazole has been shown to be efficacious in protozoal infections such as trichomonal vaginitis, amoebiasis and giardiasis. Clinical studies have also shown that tinidazole is efficacious in the treatment of anaerobic infections including respiratory tract infections, intra-abdominal sepsis and obstetrical and gynecological infections. Since tinidazole has no activity against aerobic bacteria, it must be combined with other antibacterial agents in the treatment of mixed infections involving aerobic and anaerobic bacteria. Tinidazole has also been used successfully alone or in combination with other antimicrobial agents for prophylaxis in patients undergoing elective colonic and abdominal surgery, emergency appendectomy and gynecological surgery.